Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Given Consensus Recommendation of “Hold” by Brokerages

Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) has been assigned an average recommendation of “Hold” from the fourteen brokerages that are covering the stock, Marketbeat reports. Thirteen equities research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $20.25.

FUSN has been the subject of several recent research reports. Jefferies Financial Group reissued a “hold” rating and set a $21.00 price target (up previously from $10.00) on shares of Fusion Pharmaceuticals in a research report on Tuesday, March 19th. Leerink Partnrs cut Fusion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Tuesday, March 19th. B. Riley cut Fusion Pharmaceuticals from a “buy” rating to a “neutral” rating and lifted their price target for the company from $13.00 to $23.00 in a report on Wednesday, March 20th. Wedbush cut Fusion Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $24.00 target price on the stock. in a report on Tuesday, March 19th. Finally, Brookline Capital Management lowered shares of Fusion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, March 19th.

Fusion Pharmaceuticals Price Performance

Shares of NASDAQ FUSN opened at $21.55 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 10.64 and a current ratio of 10.64. Fusion Pharmaceuticals has a one year low of $2.31 and a one year high of $21.60. The firm has a market capitalization of $1.83 billion, a P/E ratio of -15.18 and a beta of -0.69. The company’s fifty day moving average is $21.49 and its two-hundred day moving average is $15.77.

Fusion Pharmaceuticals (NASDAQ:FUSN) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Fusion Pharmaceuticals had a negative return on equity of 48.74% and a negative net margin of 4,136.55%. Analysts forecast that Fusion Pharmaceuticals will post -1.44 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new stake in shares of Fusion Pharmaceuticals in the 1st quarter worth approximately $616,000. Bluefin Capital Management LLC acquired a new position in shares of Fusion Pharmaceuticals in the 1st quarter worth approximately $213,000. Jane Street Group LLC raised its holdings in shares of Fusion Pharmaceuticals by 2,153.4% in the 1st quarter. Jane Street Group LLC now owns 633,932 shares of the company’s stock worth $13,515,000 after purchasing an additional 605,800 shares in the last quarter. California State Teachers Retirement System bought a new stake in Fusion Pharmaceuticals during the first quarter worth approximately $832,000. Finally, KRYGER CAPITAL Ltd bought a new position in shares of Fusion Pharmaceuticals in the first quarter valued at $2,138,000. Institutional investors and hedge funds own 72.85% of the company’s stock.

About Fusion Pharmaceuticals

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.